RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Primary eosinophilic granuloma of frontal lobe. Diagnostic use of S-100 protein.
Cancer 1985 July 16
Solitary eosinophilic granuloma of the frontal lobe of the brain is a rare lesion. A 30-year-old Jordanian man with a history of recurrent bilateral chronic middle ear infections and tuberculosis presented with focal seizures. A solitary right frontotemporal mass was diagnosed by brain biopsy as an eosinophilic granuloma. Immunoperoxidase stains of virtually all histiocytes in the lesion were strongly positive for S-100. Four cases of eosinophilic granuloma and one of Letterer-Siwe disease were also examined, and virtually all histiocytes demonstrated strong S-100 positivity. In comparison, 24 reactive or infectious granulomas were examined for S-100 staining and most showed complete negativity of histiocytes in granulomas for S-100. This is the first report in the literature that has examined the results of S-100 staining in a large number of reactive or infectious granulomas and compared it with S-100 staining in eosinophilic granuloma. This report illustrates that S-100 can be useful in distinguishing eosinophilic granuloma, generally considered to be part of the larger group of histiocytic disorders known as histiocytosis X, from reactive or infectious granulomatous conditions of similar or confusing histology.
Full text links
Trending Papers
Oral Anticoagulation in Patients with Chronic Liver Disease.Medicina 2023 Februrary 13
Hashimoto's Encephalopathy: Case Series and Literature Review.Current Neurology and Neuroscience Reports 2023 Februrary 29
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.Nature Reviews. Nephrology 2023 Februrary 24
BTS clinical statement on aspiration pneumonia.Thorax 2023 Februrary
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app